Biotest AG / Key word(s): Preliminary Results 20.02.2012 09:49 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Ad-hoc RELEASE Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest: Slight increase in sales of 2.3% despite difficult market environment Dreieich, 20 February 2012. According to preliminary and unaudited figures, the Biotest Group (Plasma Proteins and Biotherapeutics) recorded sales of EUR 422.0 million in the financial year 2011, an increase of 2.3% compared to the previous year (EUR 412.5 million). Earnings before interest and tax (EBIT) of the Group (Plasma Proteins, Bio-therapeutics and Corporate) are slightly lower with EUR 41.6 million compared to the previous year's EBIT of EUR 42.9 million. The reasons for this were predominantly considerable price reductions for immunoglobulins and coagulation factors, especially within the international business, as well as the unabsorbed costs incurred in connection with the expansion of the production facility in Boca Raton, Florida, USA. Included however is a contribution from the upfront-payment of the Abbott agreement of EUR 17.4 million. The earnings after taxes of the Biotest Group with its Continuing Operations and Discontinued Operation are at EUR 48.1 million in the year 2011. Earnings after taxes of the Discontinued Operation are at EUR 29.4 million. In this amount the net profit from the sale of the Microbiological Monitoring business is included. Biotest will publish final results for the Financial Year 2011 on March 22th, 2012, the annual report will be published on the same day. The Annual General Meeting of Biotest AG will take place on May 10th, 2012 in Frankfurt a.M. Biotest Aktiengesellschaft The Executive Management Board Biotest AG Landsteinerstr. 5 D-63303 Dreieich www.biotest.de Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. About Biotest Biotest is a provider of pharmaceutical and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of application of immunology and haematology. In its Plasma Protein segment, Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In the Biotherapeutic segment, Biotest researches into the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and cancer of plasma cells. Biotest has more than 1,600 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange. Securities' ID No., ISIN ordinary shares: 522720, DE0005227201 Securities' ID No., ISIN preference shares: 522723, DE0005227235 Listing: Prime Standard Open market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart 20.02.2012 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Biotest AG LandsteinerstraÃe 5 63303 Dreieich Germany Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: investor_relations@biotest.de Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Indices: SDAX Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: Biotest AG: Slight increase in sales of 2.3% despite difficult market environment
| Source: EQS Group AG